Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing

Rhea-AI Summary

Key Figures

Private placement: $50 million Common shares: Approximately 5.17 million shares Pre-funded warrants: An additional 1.13 million shares +5 more

Private placement

$50 million

Placement announced October 8

Common shares

Approximately 5.17 million shares

Private placement

Pre-funded warrants

An additional 1.13 million shares

Private placement

Effective placement price

Approximately $7.93 per share

Private placement

Estimated net cash

Approximately $254 million

Yakira estimate before the financing, at the end of the third quarter

R&D milestone payments

Up to $1.35 billion

Bristol Myers Squibb collaboration

Commercial milestone payments

$825 million

Bristol Myers Squibb collaboration

Cumulative collaboration spending cap

$40 million

Research collaboration spending; amount incurred and remaining obligation were not specified

Historical Context

1 past event · Latest: Oct 08

1 event

1. Oct 08

   Private placement

   24h Move

   +4.2%

   Atrium announced a $50 million private placement with share and warrant terms and projected operations through 2028.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

private placement, pre-funded warrants, rights offering, tiered royalties, +1 more

5 terms

private placement financial

"a $50 million private placement involving approximately 5.17 million common shares"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

pre-funded warrants financial

"pre-funded warrants covering an additional 1.13 million shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

rights offering financial

"conduct a rights offering that would allow all existing shareholders to participate"

A rights offering is a way for a company to raise additional money by giving existing shareholders the opportunity to buy more shares at a discounted price before they are offered to the public. It’s similar to a special sale where current owners get the first chance to buy extra items at a lower cost, allowing them to increase their investment if they choose. This process matters to investors because it can affect the value of their holdings and their ability to buy new shares at favorable terms.

View in glossary

tiered royalties financial

"and tiered royalties reaching the low double digits"

Tiered royalties are a payment structure where the percentage of earnings paid as royalties changes based on different levels of sales or production. For example, a company might pay a smaller percentage on initial sales and a higher percentage as sales increase beyond certain points. This system encourages higher sales by adjusting payments, making it important for investors to understand how revenue sharing may vary as a product or project grows.

proof of concept medical

"with meaningful proof of concept not expected until the second half of 2027"

A proof of concept is a demonstration that shows a new idea, product, or method is feasible and can work as intended. It serves as evidence that an approach has potential value before full development or investment begins. For investors, it helps assess the likelihood of success and reduces uncertainty about whether the concept can deliver its promised benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Yakira urges Board to explore strategic alternatives before further cash burn and dilution erode shareholder value; questions decision to raise $50 million after shares fell approximately 44% at a valuation near fifty percent of net cash

WESTPORT, Conn., Oct. 20, 2026 /PRNewswire/ -- Yakira Capital Management, Inc. ("Yakira") a shareholder of Atrium Therapeutics, Inc. (NASDAQ: RNA), today called on the Company's Board of Directors to immediately initiate a strategic review, curtail cash spending and explain its perplexing decision to issue substantial equity at a deeply depressed valuation.

On October 8, Atrium announced a $50 million private placement involving approximately 5.17 million common shares and pre-funded warrants covering an additional 1.13 million shares, at an effective price of approximately $7.93 per share.

Why raise capital after the stock has fallen approximately 44% from its pre-HARBOR level of roughly $14 per share, as opposed to raising capital when the valuation was materially higher—or conduct a rights offering that would allow all existing shareholders to participate rather than leave them facing substantial dilution? The fact that this financing extends the Company's cash runway does not establish that its timing and structure maximize shareholder value.

Three Sources of Value - and a Market Valuation That Ignores Them

We believe Atrium's value should be assessed across three components.

First, net cash. We estimate that prior to the financing, Atrium had approximately $254 million in net cash at the end of the third quarter, equivalent to approximately $14.85 per share. At a share price below $8, the stock trades at a substantial discount to estimated net cash alone.

Second, the Bristol Myers Squibb collaboration. The agreement provides for up to $1.35 billion in research and development milestone payments, $825 million in commercial milestone payments, and tiered royalties reaching the low double digits. Atrium has already earned $30 million in such milestone payments. These payments are separate from revenue recognized for research and development services under the collaboration. Atrium's research collaboration spending is subject to a cumulative $40 million cap; the amount incurred to date and the remaining obligation should be clarified so shareholders can assess the Company's remaining financial exposure.

Third, Atrium's internal development pipeline, principally ATR 1072 and ATR 1086, which offers additional potential value beyond the Company's cash and collaboration economics. At less than $8 per share, investors are paying substantially less than our estimate of Atrium's net cash value alone, before assigning any value to the BMS collaboration or Atrium's internal pipeline. At these levels the market is assigning an extremely negative value to these pipeline assets - why has the Board not tested whether a strategic partner or acquirer would value them differently?

Shareholders Should Not Bear All the Risk

Atrium's lead program remains in early-stage clinical development, with meaningful proof of concept not expected until the second half of 2027. Management expects development spending to increase significantly, yet shareholders have not been given adequate visibility into the capital required to reach that milestone.

This raises a fundamental question for the Board: if Atrium may ultimately require a strategic partner or additional outside capital to fully realize the value of its programs following successful proof of concept, why should shareholders bear substantially all the clinical risk and fund the significant cash burn required to reach that point without first testing the strategic alternatives available today?

In mid-September, Yakira raised these concerns directly with management. On October 9, after the financing, we then submitted a detailed letter to Atrium's Board urging it to pursue strategic alternatives. The Board has not responded. Having made efforts to engage privately, we believe it is now necessary to publicly call for action to protect shareholder value.

Yakira Calls on the Board to Act

• Immediately initiate a strategic review with independent financial advisors, to evaluate partnerships, licensing transactions, asset sales, a merger or a sale of the Company.
• Preserve shareholder capital through disciplined spending controls and transparent estimates of the capital required to reach key clinical milestones.
• Explain the financing decision, including why capital was raised at this valuation and whether alternatives—including a rights offering—were adequately considered.

A strategic review does not require the Board to accept a transaction. It requires the Board to determine whether a better risk-adjusted outcome is available before more shareholder capital is committed. If management believes Atrium's pipeline has substantial value, potential pharmaceutical partners and acquirers should be given the opportunity to establish what that value is worth.

The Board's responsibility is to maximize long-term shareholder value, not simply finance the continuation of the standalone strategy. We urge the Board to act now, before further cash burn and dilution erode the value shareholders are entitled to realize.

Media Contact
Bruce Kallins
President
Yakira Capital Management
bkallins@yakirapartners.com

View original content:https://www.prnewswire.com/news-releases/yakira-capital-management-calls-on-atrium-therapeutics-to-launch-strategic-review-curb-cash-spending-and-explain-dilutive-financing-302913438.html

SOURCE Yakira Capital Management